Upgrade to SI Premium - Free Trial

Enanta Pharma (ENTA)

13.06 -0.36 (2.68%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/10/26)

Latest Headlines

Enanta Pharmaceuticals sets up $75M at-the-market stock offering July 2, 2026 4:58 PM - StreetInsider Form 8-K ENANTA PHARMACEUTICALS For: Jul 02 July 2, 2026 4:57 PM - SEC Filing Form 424B5 ENANTA PHARMACEUTICALS July 2, 2026 4:54 PM - SEC Filing Enanta Pharma loses appeal in Pfizer Paxlovid patent case June 23, 2026 5:30 PM - StreetInsider Form 8-K ENANTA PHARMACEUTICALS For: Jun 23 June 23, 2026 5:28 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Enanta Pharmaceuticals (ENTA) June 23, 2026 6:52 AM - StreetInsider Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus June 23, 2026 5:10 AM - BizWire Form 8-K ENANTA PHARMACEUTICALS For: Jun 18 June 18, 2026 7:13 AM - SEC Filing Enanta advances RSV drug zelicapavir into late-stage trials June 18, 2026 7:01 AM - StreetInsider Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) June 18, 2026 7:00 AM - BizWire Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference May 28, 2026 7:00 AM - BizWire Form S-8 ENANTA PHARMACEUTICALS May 13, 2026 7:26 AM - SEC Filing Form 10-Q ENANTA PHARMACEUTICALS For: Mar 31 May 13, 2026 7:01 AM - SEC Filing Form 8-K ENANTA PHARMACEUTICALS For: May 11 May 11, 2026 4:06 PM - SEC Filing Enanta Pharma (ENTA) Tops Q2 EPS by 12c May 11, 2026 4:01 PM - StreetInsider Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 May 11, 2026 4:01 PM - BizWire Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 May 4, 2026 7:00 AM - BizWire Full Article List